Protagonist Therapeutics’ rusfertide could have preliminary data next year from its Phase 3 test in polycythemia vera. If the peptide drug wins FDA approval in this rare blood disorder, Takeda will lead its commercialization.
Takeda Puts Up $300M to Partner on Protagonist Drug for Rare Blood Disease
